Apollo Endosurgery to Be Acquired by Boston Scientific
February 1, 2023
Cooley advised Apollo Endosurgery, a medical device company, on its agreement to be acquired by Boston Scientific in an all-cash transaction with an enterprise value of approximately $615 million.
Amryt Pharma to Sell to Chiesi Farmaceutici in $1.48 Billion Cross-Border Transaction
January 9, 2023
Cooley advised Amryt Pharma, a Dublin, Ireland-based commercial-stage biopharmaceutical company, on its definitive agreement to be acquired by Chiesi Farmaceutici, a Parma, Italy-based research-focused biopharmaceuticals and healthcare group, in a $1.48 billion cash and contingent value right (CVR) transaction. Partners Bill Sorabella, Claire Keast-Butler and Bill Roegge led the joint US and UK Cooley team advising Amryt.
Y-mAbs Therapeutics Agrees to Acquisition by SERB Pharmaceuticals
August 5, 2025
Cooley advised Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, on its definitive merger agreement with SERB Pharmaceuticals. Under the agreement, SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA, in an all-cash transaction representing an equity value of approximately $412 million.
Cooley advised Tenable, an exposure management company, on its definitive agreement to acquire Apex Security, an innovator in securing the rapidly expanding artificial intelligence attack surface.
Cooley advised Feedzai, a global leader in fraud and financial crime prevention, on its acquisition of Demyst, including Demyst’s Zonic data workflow orchestration platform, intellectual property and sophisticated data-integration capabilities.